DMRA
The table below shows Damora Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.73M | -$18.62M | -$36.91M | -$42.93M | -$52.31M | -$38.20M |
| Capital expenditure | - | - | - | $196.00K | $223.00K | - |
| Investing cash flow | -$17.37M | $11.65M | $22.33M | $12.38M | -$48.05M | - |
| Dividends paid | - | - | - | - | - | - |
Damora Therapeutics, Inc. reported operating cash flow of -$6.73M for fiscal year 2025. That is up 63.9% from -$18.62M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$19.33M (FY 2019) to -$6.73M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $266.84M | - | $2.88M | $507.00K | - | $187.39M |